BibTex RIS Kaynak Göster

Oksaliplatin-Temelli Rejim Altında Progresyon Gösteren Metastatik Kolorektal Kanserli Hastalarda Modifiye Folfiri-Bevasizumab Rejimi

Yıl 2017, Yıl: 2017 Sayı: 1, 53 - 59, 01.03.2017

Doğan Koca Davut Demir Oğuzhan Özdemir Hüseyin Akdeniz Mehmet Kurt

Öz

İlk-sıra tedavide oksaliplatin-temelli rejim alan metastatik kolorektal kanserli (mKRK) hastalarda ikinci-sıra tedavide modifiye FOLFIRI-Bevacizumab (mFOLFIRI-B) rejiminin etkinlik ve tolerabilitesi araştırıldı. Materyal ve Metot: Çalışmaya ilk-sıra tedavide oksaliplatin-temelli rejim alan, ardından progresyon gözlenen ve ikinci-sıra tedavide mFOLFIRI-B rejimi alan mKRK’li hastalar alındı. Toksisite ve etkinlik ile ilgili veriler retrospektif olarak değerlendirildi.Bulgular: Toplam 172 mKRK’li hasta ikinci-sıra tedavide mFOLFIRI-B rejimi almıştı. Hastaların %39,5’inde objektif cevap, 9,0 aylık (7,6 ile 10,3 arası) median progresyonsuz yaşam, 19,0 aylık (15,1 ile 26,2 arası) median tüm yaşam saptandı. Grade 3/4 toksisite %33,7 oranında tespit edildi. Grade 3/4 hematolojik toksisite %31,9 oranında tespit edildi. Sonuç: Sonuç olarak mKRK’li hastalarda oksaliplatin-temelli rejim sonrası ikinci-sıra tedavide mFOLFIRI-B rejimi etkili ve güvenilir bir tedavi rejimidir.

Anahtar Kelimeler

metastatik kolorektal kanser ikinci-sıra kemoterapi rejimi modifiye FOLFIRI-Bevacizumab rejimi

Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen

Yıl 2017, Yıl: 2017 Sayı: 1, 53 - 59, 01.03.2017

Doğan Koca Davut Demir Oğuzhan Özdemir Hüseyin Akdeniz Mehmet Kurt

Öz

We aimed to investigate the efficacy and tolerability of modified FOLFIRI-Bevacizumab (mFOLFIRI-B) regime in the secondline treatment of metastatic colorectal cancer (mCRC) patients who received oxaliplatin-based regimen in the first-line treatment. Material and Method: The patients treated with mFOLFIRI-B regimen in second-line therapy who had progressed after oxaliplatin- based chemotherapy were included in this study. The datas of toxicity and efficacy of the regimen were retrospectively evaluated. Results: Total 172 mCRC patients had received mFOLFIRI-B regime in the second-line treatment. 39.5% objective response rate, 9.0 months (7.6 to 10.3) median progression-free survival, 19.0 months (15.1 to 26.2) median overall survival were found. Grade 3/4 toxicity was observed in 33.7%. Grade 3/4 hematologic toxicity was most frequently observed toxicity (31.9%). Conclusion: mFOLFIRI-B is an efficient and safe regimen for the second-line treatment of mCRC patients after the oxaliplatinbased regimen.

Anahtar Kelimeler

metastatic colorectal cancer second-line chemotherapy modified FOLFIRI-Bevacizumab

Toplam 0 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA79EN39HF
Bölüm Araştırma Makalesi
Yazarlar

Doğan Koca Bu kişi benim

Davut Demir Bu kişi benim

Oğuzhan Özdemir Bu kişi benim

Hüseyin Akdeniz Bu kişi benim

Mehmet Kurt Bu kişi benim

Yayımlanma Tarihi 1 Mart 2017
Yayımlandığı Sayı Yıl 2017 Yıl: 2017 Sayı: 1

Kaynak Göster

APA Koca, D., Demir, D., Özdemir, O., Akdeniz, H., vd. (2017). Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas Journal of Medical Sciences, 7(1), 53-59.
AMA Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. Nisan 2017;7(1):53-59.
Chicago Koca, Doğan, Davut Demir, Oğuzhan Özdemir, Hüseyin Akdeniz, ve Mehmet Kurt. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences 7, sy. 1 (Nisan 2017): 53-59.
EndNote Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M (01 Nisan 2017) Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas Journal of Medical Sciences 7 1 53–59.
IEEE D. Koca, D. Demir, O. Özdemir, H. Akdeniz, ve M. Kurt, “Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”, KAFKAS TIP BİL DERG, c. 7, sy. 1, ss. 53–59, 2017.
ISNAD Koca, Doğan vd. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences 7/1 (Nisan 2017), 53-59.
JAMA Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. 2017;7:53–59.
MLA Koca, Doğan vd. “Modified FOLFIRI-Bevacizumab Regimen in the Patients With Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen”. Kafkas Journal of Medical Sciences, c. 7, sy. 1, 2017, ss. 53-59.
Vancouver Koca D, Demir D, Özdemir O, Akdeniz H, Kurt M. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. KAFKAS TIP BİL DERG. 2017;7(1):53-9.